Literature DB >> 7295494

Comparison of single and divided daily dose spironolactone in the control of hypertension.

G M Bell, L Fananapazir, J L Anderton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7295494      PMCID: PMC1401883          DOI: 10.1111/j.1365-2125.1981.tb01271.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  9 in total

1.  RELATIONSHIP OF PLASMA ALDADIENE LEVELS AND ANTIMINERALOCORTICOID EFFECTS OF SPIRONOLACTONE IN THE LABORATORY.

Authors:  C M KAGAWA; D J BOUSKA; M L ANDERSON
Journal:  Proc Soc Exp Biol Med       Date:  1964-03

2.  Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.

Authors:  C G Dahlöf; P Lundborg; B A Persson; C G Regårdh
Journal:  Drug Metab Dispos       Date:  1979 Mar-Apr       Impact factor: 3.922

Review 3.  Spironolactone.

Authors:  H R Ochs; D J Greenblatt; G Bodem; T W Smith
Journal:  Am Heart J       Date:  1978-09       Impact factor: 4.749

4.  Antihypertensive responses to spironolactone in normal renin hypertension.

Authors:  R I Ogilvie; K M Piafsky; J Ruedy
Journal:  Clin Pharmacol Ther       Date:  1978-11       Impact factor: 6.875

5.  Comparison of a single-dose and twice-a-day spironolactone therapy in mild hypertension.

Authors:  A Ludbrook; M Dynon; F A Mendelsohn; W J Louis
Journal:  Med J Aust       Date:  1980-02-09       Impact factor: 7.738

6.  Spironolactone. I. Disposition and metabolism.

Authors:  A Karim; J Zagarella; J Hribar; M Dooley
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

7.  Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.

Authors:  A Karim; J Zagarella; T C Hutsell; M Dooley
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

8.  A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma.

Authors:  N GOCHMAN; C L GANTT
Journal:  J Pharmacol Exp Ther       Date:  1962-03       Impact factor: 4.030

9.  Spironolactone and canrenoate-K: relative potency at steady state.

Authors:  L Ramsay; M Asbury; J Shelton; I Harrison
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

  9 in total
  2 in total

1.  What is the role of aldosterone excess in resistant hypertension and how should it be investigated and treated?

Authors:  Domenic A Sica
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

2.  Treatment considerations with aldosterone receptor antagonists.

Authors:  Domenic A Sica; John M Flack
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-10-04       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.